Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Apr 17  •  04:00PM ET
44.90
Dollar change
+4.49
Percentage change
11.11
%
Apr 15, 4:05 AMMomentum from March GLOW2 Phase 3 success and analyst upgrades powers 24%+ premarket surge.
Index
RUT
P/E
-
EPS (ttm)
-4.32
Insider Own
7.14%
Shs Outstand
61.76M
Perf Week
4.15%
Market Cap
2.78B
Forward P/E
-
EPS next Y
-3.42
Insider Trans
140.36%
Shs Float
57.43M
Perf Month
103.35%
Enterprise Value
2.73B
PEG
-
EPS next Q
-0.96
Inst Own
88.32%
Perf Quarter
68.16%
Income
-229.97M
P/S
-
EPS this Y
13.21%
Inst Trans
19.46%
Perf Half Y
201.75%
Sales
0.00M
P/B
17.62
EPS next Y
8.88%
ROA
-66.94%
Perf YTD
60.59%
Book/sh
2.55
P/C
13.23
EPS next 5Y
35.18%
ROE
-149.49%
52W High
46.67 -3.79%
Perf Year
1480.99%
Cash/sh
3.39
P/FCF
-
EPS past 3/5Y
12.22% -8.23%
ROIC
-75.52%
52W Low
2.34 1818.80%
Perf 3Y
810.75%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-
Volatility
9.11% 10.61%
Perf 5Y
-60.92%
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
-29.02%
Oper. Margin
-
ATR (14)
3.72
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
4.72
Sales Y/Y TTM
-
Profit Margin
-
RSI (14)
65.02
Dividend Gr. 3/5Y
- -
Current Ratio
4.72
EPS Q/Q
-24.42%
SMA20
20.79%
Beta
2.34
Payout
-
Debt/Eq
1.01
Sales Q/Q
-
SMA50
51.36%
Rel Volume
0.95
Prev Close
40.41
Employees
124
LT Debt/Eq
0.93
SMA200
127.90%
Avg Volume
1.10M
Price
44.90
IPO
Oct 04, 2018
Option/Short
Yes / Yes
Trades
Volume
1,040,552
Change
11.11%
Date Action Analyst Rating Change Price Target Change
Nov-11-25Upgrade H.C. Wainwright Neutral → Buy $24
Oct-24-25Upgrade JP Morgan Neutral → Overweight $24
Sep-25-25Upgrade Barclays Underweight → Equal Weight $17
Sep-22-25Initiated Jefferies Buy $15
Aug-14-25Upgrade JP Morgan Underweight → Neutral $15
Dec-09-24Upgrade Jefferies Hold → Buy $20
Sep-05-24Initiated H.C. Wainwright Neutral $3
Dec-11-23Resumed Goldman Sell $2
Nov-17-23Upgrade CapitalOne Equal Weight → Overweight $7 → $12
Jul-27-23Downgrade UBS Buy → Neutral $15 → $4
Mar-31-26 04:45PM
Mar-27-26 08:23AM
Mar-26-26 06:46AM
06:00AM
Feb-06-26 11:31AM
07:00AM Loading…
Feb-04-26 07:00AM
Jan-07-26 08:19PM
Dec-30-25 08:45AM
Dec-22-25 10:11AM
Dec-18-25 08:26PM
Dec-16-25 10:55PM
Dec-15-25 04:01PM
Nov-14-25 07:36AM
Nov-13-25 04:05PM
Nov-12-25 05:48PM
07:00AM Loading…
Nov-05-25 07:00AM
Sep-15-25 07:00AM
Sep-12-25 11:30AM
Sep-02-25 08:00AM
Aug-29-25 03:05PM
Aug-26-25 07:52PM
Aug-19-25 02:18PM
Aug-14-25 11:41AM
Aug-13-25 04:00PM
Jul-10-25 08:00AM
Jun-25-25 04:45PM
Jun-24-25 05:51AM
Jun-13-25 11:30AM
May-29-25 09:32PM
May-15-25 11:04AM
04:15PM Loading…
May-14-25 04:15PM
May-01-25 11:43PM
Apr-01-25 09:35AM
Mar-28-25 09:45AM
Mar-27-25 04:01PM
Mar-26-25 03:58PM
Mar-10-25 04:39PM
Feb-04-25 07:30AM
Jan-13-25 04:26PM
Jan-07-25 06:00AM
Dec-09-24 09:18PM
12:33PM
Nov-25-24 09:55AM
Nov-14-24 04:01PM
Nov-11-24 06:15AM
Oct-14-24 05:35PM
Sep-23-24 06:00AM
Sep-17-24 04:05PM
Sep-13-24 11:30AM
Aug-16-24 10:42AM
Aug-14-24 09:54PM
04:01PM
Jul-10-24 12:00PM
Jun-20-24 08:23AM
Jun-14-24 11:30AM
May-29-24 04:36PM
May-16-24 12:51PM
May-15-24 10:55PM
04:01PM
May-14-24 07:31AM
May-13-24 07:32PM
May-02-24 04:30PM
Apr-04-24 12:09PM
Apr-01-24 05:04PM
12:00PM
Mar-29-24 10:36AM
Mar-28-24 11:53AM
08:32AM
06:30AM
Mar-26-24 06:15AM
Jan-30-24 06:30AM
Jan-04-24 04:15PM
Dec-14-23 11:30AM
Nov-21-23 04:15PM
Nov-15-23 08:00AM
Nov-14-23 06:09PM
04:01PM
Nov-06-23 05:00AM
Nov-01-23 11:21PM
Oct-17-23 01:44AM
Oct-11-23 06:00AM
Sep-13-23 11:30AM
Sep-08-23 06:00AM
Sep-07-23 06:00AM
Aug-16-23 10:26AM
Aug-14-23 07:31PM
04:01PM
08:34AM
07:15AM
Aug-02-23 10:09AM
Jul-27-23 02:30AM
Jul-26-23 06:42AM
Jul-25-23 09:16AM
Jul-24-23 06:26AM
06:09AM
06:00AM
Jun-14-23 11:30AM
May-30-23 04:15PM
11:14AM
May-16-23 07:44AM
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BORGESON JOHN A.Chief Financial OfficerApr 15 '26Option Exercise1.0428,61429,759211,930Apr 16 05:00 PM
BORGESON JOHN A.Chief Financial OfficerApr 02 '26Option Exercise1.0430,00031,200213,316Apr 02 08:26 PM
BORGESON JOHN A.Chief Financial OfficerApr 02 '26Sale39.9230,0001,197,488183,316Apr 02 08:26 PM
JOHN BORGESONOfficerApr 02 '26Proposed Sale42.8130,0001,284,300Apr 02 04:23 PM
PERLROTH VICTORChairman and CEOMar 25 '26Option Exercise1.04300,000312,0002,395,538Mar 27 06:08 PM
BAKER BROS. ADVISORS LPDirectorDec 18 '25Buy23.002,608,69660,000,00818,358,772Dec 19 04:06 PM
BORGESON JOHN A.See RemarksJun 17 '25Sale3.657232,640183,316Jun 17 08:15 PM